Patrick Waters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9164595/publications.pdf

Version: 2024-02-01

203 papers 27,651 citations

72 h-index 161 g-index

209 all docs 209 docs citations

times ranked

209

14537 citing authors

#	Article	IF	CITATIONS
1	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
2	Frequency of MOG-IgG in cerebrospinal fluid versus serum. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 334-335.	0.9	18
3	Utility of Live Cell-Based Assays for Autoimmune Neurology Diagnostics. journal of applied laboratory medicine, The, 2022, 7, 391-393.	0.6	4
4	Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	43
5	Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. Brain, 2022, 145, 2742-2754.	3.7	33
6	Detection and significance of neuronal autoantibodies in patients with meningoencephalitis in Vientiane, Lao PDR. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 959-965.	0.7	1
7	Serum MOG-lgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	1.4	12
8	Rituximab abrogates aquaporin-4–specific germinal center activity in patients with neuromyelitis optica spectrum disorders. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
9	Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 995-1000.	0.9	19
10	Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice. Neurological Sciences, 2021, 42, 73-80.	0.9	14
11	Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	58
12	Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 291-294.	0.9	34
13	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	2.8	33
14	Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle and Nerve, 2021, 63, 262-267.	1.0	8
15	The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis. Journal of Neurology, 2021, 268, 1689-1707.	1.8	51
16	Intrathecal Production of MOG-IgG. Neurology, 2021, 97, 12-13.	1.5	3
17	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
18	Leucineâ€Rich Gliomaâ€Inactivated 1 versus Contactinâ€Associated Proteinâ€Iike 2 Antibody Neuropathic Pain: Clinical and Biological Comparisons. Annals of Neurology, 2021, 90, 683-690.	2.8	27

#	Article	IF	Citations
19	Progressive encephalomyelitis with rigidity: A Taiwanese case and review of literature. Clinical Neurology and Neurosurgery, 2021, 208, 106807.	0.6	7
20	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
21	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	1.1	8
22	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	2.8	27
23	Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Translational Psychiatry, 2021, 11, 566.	2.4	19
24	Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open, 2021, 11, e055392.	0.8	30
25	Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 2021, 58, 103408.	0.9	0
26	Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurology, 2020, 77, 82.	4.5	213
27	Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. Multiple Sclerosis and Related Disorders, 2020, 40, 101939.	0.9	24
28	Randomized Placeboâ€Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Annals of Neurology, 2020, 87, 313-323.	2.8	106
29	Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus. Annals of Neurology, 2020, 88, 1244-1250.	2.8	16
30	Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Relapse With COVID-19. Frontiers in Neurology, 2020, 11, 598531.	1.1	30
31	Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain, 2020, 143, 1731-1745.	3.7	74
32	Bone health in neuromyelitis optica: Bone mineral density and fractures. Multiple Sclerosis and Related Disorders, 2020, 42, 102080.	0.9	3
33	We need to talk about MOG. Neurology, 2020, 95, 55-56.	1.5	0
34	Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2. Practical Neurology, 2020, 20, 377-384.	0.5	39
35	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	1.1	27
36	Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1126-1128.	0.9	66

3

#	Article	IF	Citations
37	Cell-based assays for the detection of MOG antibodies: a comparative study. Journal of Neurology, 2020, 267, 3555-3564.	1.8	44
38	International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7 , .	3.1	180
39	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	1.8	17
40	Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort. Frontiers in Neurology, 2020, 11 , 525933 .	1.1	12
41	Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	6
42	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, 1028.	1.1	56
43	Myelin oligodendrocyte glycoprotein CSF testing needs testing. Neurology, 2019, 93, 871-872.	1.5	4
44	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	0.9	49
45	Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. Journal of Immunology, 2019, 202, 2210-2219.	0.4	22
46	GABA _A receptor autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e552.	3.1	42
47	Acquired neuromyotonia in thymomaâ€associated myasthenia gravis: a clinical and serological study. European Journal of Neurology, 2019, 26, 992-999.	1.7	17
48	A multicenter comparison of MOG-IgG cell-based assays. Neurology, 2019, 92, e1250-e1255.	1.5	135
49	Classifying the antibody-negative NMO syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e626.	3.1	17
50	Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology, 2019, 15, 89-102.	4.9	439
51	Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-lgG-associated encephalomyelitis. Multiple Sclerosis Journal, 2019, 25, 585-590.	1.4	26
52	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	2.3	43
53	Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain, 2018, 141, 1063-1074.	3.7	76
54	The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141, 348-356.	3.7	272

#	Article	IF	CITATIONS
55	Nâ€methylâ€Dâ€aspartate receptor antibody production from germinal center reactions: Therapeutic implications. Annals of Neurology, 2018, 83, 553-561.	2.8	95
56	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	2.7	86
57	LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 526-534.	0.9	146
58	Predictors of outcome in a large retrospective cohort of patients with transverse myelitis. Multiple Sclerosis Journal, 2018, 24, 1743-1752.	1.4	12
59	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. JAMA Neurology, 2018, 75, 65.	4.5	184
60	38.3 ONGOING GERMINAL CENTRE REACTIONS CONTRIBUTE TO N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTIBODY PRODUCTION IN NMDAR-ANTIBODY ENCEPHALITIS. Schizophrenia Bulletin, 2018, 44, S61-S61.	2.3	0
61	Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. Journal of Neuroinflammation, 2018, 15, 302.	3.1	82
62	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurology, 2018, 75, 1519.	4.5	43
63	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	3.7	100
64	Glutamate receptor $\hat{l}'2$ serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, e714-e723.	1.5	43
65	Antiglycine receptor antibody related disease: a case series and literature review. European Journal of Neurology, 2018, 25, 1290-1298.	1.7	51
66	Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features. PLoS ONE, 2018, 13, e0193723.	1.1	23
67	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 132-136.	0.9	132
68	Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 165-169.	0.9	37
69	G ₂ A ₁ B ₃ A _A receptor antibodies and their clinical associations. Neurology, 2017, 88, 1010-1011.	1.5	1
70	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 353-361.	0.9	124
71	Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity. Neurologist, 2017, 22, 101-102.	0.4	11
72	IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e357.	3.1	53

#	Article	IF	CITATIONS
73	Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. Sleep, 2017, 40, .	0.6	32
74	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	0.9	108
75	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain, 2017, 140, 617-627.	3.7	208
76	Detection of NMDARs Antibodies in Encephalitis. Methods in Molecular Biology, 2017, 1677, 117-126.	0.4	5
77	Pathogenic potential of antibodies to the <scp>GABA_B</scp> receptor. Epilepsia Open, 2017, 2, 355-359.	1.3	30
78	Reasons for early immunotherapy in 103 patients with faciobrachial dystonic seizures: Effect on short and long-term outcomes. Journal of the Neurological Sciences, 2017, 381, 122-123.	0.3	0
79	1633â€Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	0.9	0
80	Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 811-817.	0.9	121
81	Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. Multiple Sclerosis Journal, 2017, 23, 1104-1111.	1.4	37
82	Peripheral VH4+Âplasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathologica, 2017, 133, 43-60.	3.9	30
83	PO133â€Neuromyelitis optica spectrum disease preceded by three year history of intermittent gastro-intestinal dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A47.3-A47.	0.9	0
84	1645â€Vgkc is dead: long live lgi1- and caspr2-antibodies. intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.2-A10.	0.9	0
85	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	3.7	527
86	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies: Evidence for relative pathogenicity. Journal of the Neurological Sciences, 2017, 381, 77-78.	0.3	0
87	PO130â€A case of neuromyelitis optica spectrum disease, necrotizing myositis and breast cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.3-A46.	0.9	0
88	PO147â€Myelin oligodendrocyte glycoprotein-antibody disease in the uk. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A51.2-A51.	0.9	0
89	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, 95.	2.4	35
90	Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Developmental Medicine and Child Neurology, 2016, 58, 836-841.	1.1	29

#	Article	IF	CITATIONS
91	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	0.9	228
92	Detection methods for neural autoantibodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 147-163.	1.0	26
93	Neurexin-3α. Neurology, 2016, 86, 2222-2223.	1.5	6
94	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	1.7	39
95	Neuronal antibodies in pediatric epilepsy: Clinical features and longâ€ŧerm outcomes of a historical cohort not treated with immunotherapy. Epilepsia, 2016, 57, 823-831.	2.6	33
96	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	0.9	89
97	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	0.9	5
98	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	4.9	2,782
99	Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Multiple Sclerosis and Related Disorders, 2016, 7, 21-25.	0.9	36
100	Antibodies to AMPA receptors in Rasmussen's encephalitis. European Journal of Paediatric Neurology, 2016, 20, 222-227.	0.7	15
101	Isolated new onset â€~atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Journal of Neurology, 2016, 263, 370-379.	1.8	51
102	Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 79-87.	1.5	95
103	A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e88.	3.1	3
104	Antibodies to GABA _A receptor α1 and γ2 subunits. Neurology, 2015, 84, 1233-1241.	1.5	159
105	Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e121.	3.1	14
106	Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology, 2015, 84, 1177-1179.	1.5	38
107	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 470-472.	0.9	90
108	Immunoglobulin <scp>G</scp> antibodies to the <scp>N</scp> â€Methylâ€ <scp>D</scp> â€aspartate receptor are distinct from immunoglobulin <scp>A</scp> and immunoglobulin <scp>M</scp> responses. Annals of Neurology, 2015, 77, 183-183.	2.8	20

#	Article	IF	CITATIONS
109	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.5	99
110	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
111	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e81.	3.1	205
112	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	1.0	115
113	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	3.1	322
114	Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?. Journal of Neuropathology and Experimental Neurology, 2015, 74, 194-197.	0.9	6
115	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e163.	3.1	203
116	Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e160.	3.1	13
117	Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. Journal of Neuroimmunology, 2015, 289, 1-7.	1.1	40
118	GLYCINE RECEPTOR ANTIBODY—A MARKER FOR NMO/ NON-MS DEMYELINATION?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.36-e4.	0.9	0
119	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	3.1	104
120	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS ONE, 2015, 10, e0129555.	1.1	17
121	Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability. PLoS ONE, 2014, 9, e107274.	1.1	31
122	RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.63-e4.	0.9	0
123	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 2014, 82, 474-481.	1.5	743
124	Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 456-461.	0.9	70
125	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e2.	3.1	85
126	Purification of Native Surfactant Protein SP-A from Pooled Amniotic Fluid and Bronchoalveolar Lavage. Methods in Molecular Biology, 2014, 1100, 257-272.	0.4	8

#	Article	IF	CITATIONS
127	MOG-IGG IN NMO AND NMO-LIKE DISORDERS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.90-e4.	0.9	O
128	Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodiesâ€"Reply. JAMA Neurology, 2014, 71, 924.	4.5	15
129	Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55, 414-422.	2.6	66
130	Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies. JAMA Neurology, 2014, 71, 276.	4.5	519
131	Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres. Journal of Neuroimmunology, 2014, 275, 15.	1.1	1
132	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	1.1	54
133	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	3.7	430
134	<i>N</i> å€methylâ€ <i>D</i> å€aspartate receptor antibodies in post–herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	2.2	192
135	Neuromyelitis optica MOG-lgG causes reversible lesions in mouse brain. Acta Neuropathologica Communications, 2014, 2, 35.	2.4	115
136	Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurology, 2014, 14, 93.	0.8	15
137	Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e16.	3.1	14
138	Purification of Surfactant Protein D (SP-D) from Pooled Amniotic Fluid and Bronchoalveolar Lavage. Methods in Molecular Biology, 2014, 1100, 273-290.	0.4	11
139	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nature Genetics, 2013, 45, 1061-1066.	9.4	380
140	Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 918-921.	0.9	84
141	Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. Journal of the Neurological Sciences, 2013, 335, 221-223.	0.3	33
142	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. Journal of Clinical Neuroscience, 2013, 20, 938-942.	0.8	9
143	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.4	90
144	Progressive Encephalomyelitis with Rigidity and Myoclonus: A Syndrome with Diverse Clinical Features and Antibody Responses. European Neurology, 2013, 69, 257-262.	0.6	22

#	Article	IF	CITATIONS
145	Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136, 3151-3162.	3.7	373
146	Progressive Encephalomyelitis With Rigidity and Myoclonus. JAMA Neurology, 2013, 70, 498.	4.5	51
147	Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology, 2013, 80, 2210-2216.	1.5	98
148	Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2013, 19, 1060-1067.	1.4	24
149	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. JAMA Neurology, 2013, 70, 1375.	4.5	100
150	Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 748-755.	0.9	217
151	Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54, 1028-1035.	2.6	199
152	Autoantibodies to neuronal antigens in children with newâ€onset seizures classified according to the revised <scp>ILAE</scp> organization of seizures and epilepsies. Epilepsia, 2013, 54, 2091-2100.	2.6	54
153	MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE, 2013, 8, e80695.	1.1	138
154	Acute Measles Encephalitis in Partially Vaccinated Adults. PLoS ONE, 2013, 8, e71671.	1.1	15
155	Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 437-440.	0.9	105
156	Laboratoriums Medizin, 2012, 35,	0.1	3
157	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	3.7	361
158	Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. Journal of Neurology, 2012, 259, 1566-1573.	1.8	51
159	Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology, 2012, 79, 1273-1277.	1.5	400
160	Serologic diagnosis of NMO. Neurology, 2012, 78, 665-671.	1.5	454
161	Antibodies identified by cellâ€based assays in myasthenia gravis and associated diseases. Annals of the New York Academy of Sciences, 2012, 1274, 92-98.	1.8	39
162	The search for new antigenic targets in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 123-128.	1.8	76

#	Article	IF	CITATIONS
163	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.5	177
164	Neutrophil protease inhibition reduces neuromyelitis optica–immunoglobulin G–induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	2.8	153
165	Morvan syndrome: Clinical and serological observations in 29 cases. Annals of Neurology, 2012, 72, 241-255.	2.8	470
166	Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Experimental Neurology, 2012, 234, 506-512.	2.0	112
167	Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. Acta Neurologica Scandinavica, 2012, 126, 287-291.	1.0	14
168	Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. Journal of the Neurological Sciences, 2011, 301, 71-76.	0.3	36
169	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-lgG and complement. Journal of Neuroimmunology, 2011, 235, 27-32.	1.1	31
170	Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurology, The, 2011, 10, 759-772.	4.9	549
171	Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology, 2011, 258, 464-470.	1.8	65
172	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2011, 258, 686-688.	1.8	277
173	Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. Journal of Neurology, 2011, 258, 2176-2180.	1.8	25
174	Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of Neurology, 2011, 69, 892-900.	2.8	751
175	Antiglycine-receptor encephalomyelitis with rigidity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1399-1401.	0.9	121
176	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Laboratoriums Medizin, 2011, 35, 329-342.	0.1	4
177	Absence of aquaporin-4 antibodies in patients with idiopathic intracranial hypertension. Journal of Neurology, 2010, 257, 1211-1212.	1.8	19
178	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 2010, 133, 349-361.	3.7	480
179	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.3	169
180	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133, 1655-1667.	3.7	900

#	Article	IF	Citations
181	Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 2010, 133, 2734-2748.	3.7	1,158
182	Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity, 2010, 43, 371-379.	1.2	66
183	Sjögren's syndrome myelopathy: spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1062-1068.	1.4	70
184	Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 679-682.	0.9	52
185	Structural Characterisation of Ligand-Binding Determinants in Human Lung Surfactant Protein D: Influence of Asp325. Journal of Molecular Biology, 2009, 394, 776-788.	2.0	22
186	Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis. Molecular Immunology, 2009, 46, 2363-2369.	1.0	24
187	Lung Surfactant Proteins A and D as Pattern Recognition Proteins. Advances in Experimental Medicine and Biology, 2009, 653, 74-97.	0.8	32
188	Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1069-1076.	1.4	59
189	Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1084-1084.	0.9	38
190	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	2.7	286
191	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.9	259
192	Recombinant surfactant protein-D selectively increases apoptosis in eosinophils of allergic asthmatics and enhances uptake of apoptotic eosinophils by macrophages. International Immunology, 2008, 20, 993-1007.	1.8	54
193	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. Neurology, 2008, 71, 1291-1292.	1.5	324
194	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain, 2008, 131, 3072-3080.	3.7	397
195	C1q and its growing family. Immunobiology, 2007, 212, 253-266.	0.8	174
196	Surfactant proteins SP-A and SP-D: Structure, function and receptors. Molecular Immunology, 2006, 43, 1293-1315.	1.0	468
197	Role of Ca2+in the Electrostatic Stability and the Functional Activity of the Globular Domain of Human C1qâ€. Biochemistry, 2005, 44, 14097-14109.	1.2	46
198	Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-lgG Interaction. Journal of Immunology, 2004, 172, 4351-4358.	0.4	72

#	Article	IF	CITATIONS
199	Structural and functional anatomy of the globular domain of complement protein C1q. Immunology Letters, 2004, 95, 113-128.	1.1	166
200	C1q and tumor necrosis factor superfamily: modularity and versatility. Trends in Immunology, 2004, 25, 551-561.	2.9	392
201	Use of Peptide:HLA Class II Complexes to Study Specific T Cells in Autoimmune Myasthenia Gravis. Annals of the New York Academy of Sciences, 2003, 998, 339-342.	1.8	1
202	Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. Immunology Letters, 2003, 86, 299-307.	1.1	66
203	Structural investigation of a glutathione binding site using computational analysis. Biochemical Society Transactions, 1995, 23, 382S-382S.	1.6	3